drugset
Drugs / Menjugate
last change Apr 2017 re-read 9 days ago

Menjugate

also known as Men C conjugated vaccine · MenC · Meningococcal Group C-CRM197 Conjugate Vaccine

Vaccine

Developed for
meningococcal infection · meningitis · meningococcemia · meningococcal meningitis
Investigated by
Public Health England · GlaxoSmithKline · Institute of Child Health · National Institute of Biological Standards and Control · Novartis · Novartis Vaccines
+1 more · Sanofi Pasteur, a Sanofi Company

Trials 5

today NCT01359449 · Ph 3 NCT01266993 · Ph 3 NCT00625677 · Ph 4 NCT00197808 · Ph 4 NCT00262002 · Ph 2
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00262002 Sep 2004 → Jul 2005 meningococcemia Novartis Vaccines Completed No outcome recorded
Phase 32 trials
Phase 3 NCT01359449 May 2011 → Jul 2012 meningitis, meningococcal infection Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 3 NCT01266993 Jan 2011 → Mar 2014 meningococcal infection GlaxoSmithKline Completed No outcome recorded
Phase 42 trials
Phase 4 NCT00625677 Feb 2008 → Mar 2010 meningococcal infection, pneumococcal infection Public Health England Completed No outcome recorded
Phase 4 NCT00197808 Apr 2005 → Jan 2010 meningococcal infection, pneumococcal infection Public Health England Completed No outcome recorded
Comparator or background therapy13 trials
Phase 1 NCT01889836 Comparator May → Dec 2014 meningococcal meningitis The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) Completed No outcome recorded
Phase 1 NCT06165276 Comparator Jul 2006 → Aug 2008 meningococcal infection Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 2 NCT01171989 Comparator Aug → Dec 2010 diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01098474 Comparator Jul 2010 → Apr 2011 tuberculosis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01090453 Comparator May 2010 → Oct 2011 diphtheria, haemophilus infectious disease, hepatitis B virus infection, meningococcal infection +2 GlaxoSmithKline Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2016-05-13 GlaxoSmithKline Results GSK’s Bexsero®▼achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children gsk.com ↗
In addition, concomitant administration of Menjugate® (Meningococcal Group C Conjugate Vaccine) with Bexsero in infants was shown to be non-inferior to Menjugate alone, with similar safety profiles.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

FieldValueCited text
Known as Menjugate “Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.” NCT01359449 ↗
16

NCT00674583 ↗

NCT00262002 ↗

NCT00197808 ↗

NCT00129116 ↗

NCT00657709 ↗

NCT01090453 ↗

NCT01098474 ↗

NCT01889836 ↗

NCT00871338 ↗

NCT01144663 ↗

Show 6 more sources
Known as Men C conjugated vaccine “Menjugate (Men C conjugated vaccine)” NCT00262002 ↗
Known as MenC ClinicalTrials.gov intervention name — accepted as the source's own label NCT01359449 ↗
Known as Meningococcal Group C-CRM197 Conjugate Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT06165276 ↗
Modality Vaccine “Men C conjugated vaccine” NCT00262002 ↗
Route Intramuscular “Menjugate was injected IM in the anterolateral area of the right thigh” NCT00262002 ↗